SpringWorks Therapeutics Inc (NAS:SWTX)
$ 36.12 -0.08 (-0.22%) Market Cap: 2.68 Bil Enterprise Value: 2.25 Bil PE Ratio: 0 PB Ratio: 4.71 GF Score: 40/100

SpringWorks Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 08, 2024 / 03:30PM GMT
Release Date Price: $41.53 (+9.40%)
Anupam Rama JPMorgan;Analyst

All right. Welcome, everybody, to the 42nd Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by the team, Malcolm Kuno, Priyanka Grover, and LaRhea Hall. I want to kick off Monday morning with the SpringWorks, and speaking on behalf of the company, we have CEO, Saqib Islam. Saqib?

Saqib Islam SpringWorks Therapeutics
Inc. - CEO

Thanks, Anupam. It's a pleasure to be here as always, and we appreciate you and the JPMorgan team hosting us.

Before we begin, I'll remind everyone that today's presentation includes some forward-looking statements. So at SpringWorks, we develop therapies that can meaningfully improve the lives of patients with severe rare diseases and cancer. With the recent FDA approval of Ogsiveo, we are proud to be executing on our commitment to patients and their families. Beyond Ogsiveo, we believe that we have best-in-class data with mirdametinib, our MEK inhibitor that could support a second product approval for patients

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot